Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 2/20 | 0.35 |
| ▸ | AMD1 | P17707 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798140 | 0.86 | RXFP1 (0.40) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL17889824 | 0.86 | RXFP1 (0.40) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL12779230 | 0.85 | RXFP1 (0.40) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL1799630 | 0.83 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL5319686 | 0.83 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL17889809 | 0.83 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL5318875 | 0.83 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL23776534 | 0.82 | AHCY (0.47) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL18512602 | 0.82 | AHCY (0.47) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL5369830 | 0.81 | TYMP (0.39) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265111-B2 | Adenosine analogues and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-04 | — | — | US | disclosed |
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| EP-1375508-A1 | N6-substituted adenosine analogues and their use as pharmaceutical agents | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | ADORA1, ADORA2A, ADORA2B | PI4KA 845/4885PI4K2B 504/4885PI4K2A 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.